Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by DryBoneson May 03, 2018 9:32pm

106 Views

Post# 27980407

RE:RE:Priority review voucher- what is it?

Priority Review Vouchers Awarded to Date
Date Voucher Awarded	Voucher Type	Company Voucher Awarded to:
2009	Tropical Disease	Novartis
2012	Tropical Disease	Janssen
2014	Rare Pediatric Disease	BioMarin
2014	Tropical Disease	Knight Therapeutics
2015	Rare Pediatric Disease	United Therapeutics
2015	Rare Pediatric Disease	Asklepion Pharmaceuticals
2015	Rare Pediatric Disease	Wellstat Therapeutics
2015	Rare Pediatric Disease	Alexion Pharmaceuticals
2015	Rare Pediatric Disease	Alexion Pharmaceuticals
2016	Tropical Disease	PaxVax Bermuda
2016	Rare Pediatric Disease	Sarepta Therapeutics
2016	Rare Pediatric Disease	Ionis Pharmaceuticals
2017	Rare Pediatric Disease	Marathon Pharmaceuticals
2017	Rare Pediatric Disease	BioMarin
2017	Tropical Disease	Chemo Research, S.L.
2017	Rare Pediatric Disease	Novartis
2017	Rare Pediatric Disease	Ultragenyx Pharmaceutical
2017	Rare Pediatric Disease	Spark Therapeutics
2018	Rare Pediatric Disease	Ultragenyx